Latest news with #ClinicalPlatform
Yahoo
09-07-2025
- Business
- Yahoo
Veeva Expands Market Reach Through Targeted Strategic Partnerships
Veeva Systems VEEV is making smart moves in 2025 by expanding its network of high-impact partnerships, helping the company grow faster and become more deeply embedded in how life sciences firms operate. In June, Veeva teamed up with the Sarah Cannon Research Institute to roll out its Clinical Platform across over 200 oncology research sites—a major endorsement of its technology for streamlining cancer trials. In the same month, Astellas chose Veeva's Vault CRM, including its China-specific version, as its global standard for commercial operations. Earlier, in January, Veeva partnered with Zifo to help pharma companies integrate lab quality data more easily into Veeva LIMS, speeding up system rollouts. On the AI front, EVERSANA joined Veeva's partner program in April to co-develop generative AI tools for content creation and customer engagement. Veeva also advanced its regulatory capabilities this year through partnerships with DNAnexus and Accumulus Synergy, making it easier for pharma companies to manage global filings securely and efficiently. These partnerships are helping Veeva drive faster adoption, deepen customer relationships, and unlock new growth opportunities across clinical research, AI-driven engagement, and regulatory compliance. By teaming up with key players, Veeva is expanding its reach and making its platform more indispensable, strengthening both its competitive edge and long-term revenue potential. IQVIA Holdings IQV is strengthening its position by expanding into AI-driven solutions across clinical trials and commercialization. In June 2025, the company launched 'AI agents' designed to streamline everything from patient recruitment to trial coordination. It also partnered with NVIDIA in January 2025 to boost its 'Healthcare-grade AI,' enabling automated workflows and advanced analytics across R&D and real-world data platforms. Oracle ORCL continues to update its life sciences platforms, focusing on automation and cloud-based scalability. In March 2025, Oracle made Argus Safety 25.1 Cloud generally available for new SaaS customers, incorporating enhanced automation and workflow management features for pharmacovigilance and case processing. Earlier, in October 2024, Oracle unveiled its next-generation Electronic Health Record system, built on Oracle Cloud Infrastructure, with AI embedded into care workflows such as documentation and appointment preparation. The company also continues to enhance its Clinical One platform, focusing on unifying trial design, randomization, supply management, and data capture in a single cloud-native environment. Shares of VEEV have gained 33.5% in the year-to-date period compared with the industry's growth of 8.1%. Image Source: Zacks Investment Research From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.25, above the industry average. VEEV carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oracle Corporation (ORCL) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
11-06-2025
- Business
- Yahoo
Veeva Systems (NYSE:VEEV) Powers Medtech Trials with Expanded Clinical Platform Adoption
Veeva Systems recently announced a significant milestone with over 50 medtech companies adopting its Clinical Platform applications, a move that aligns with stringent regulatory demands and shifting market dynamics. The company's stock increased by 22% over the last quarter, boosted by solid earnings with a revenue surge to $759 million and strategic guidance for the coming fiscal year. Simultaneously, broader market trends like easing inflation and positive trade talks between the U.S. and China likely provided a supportive backdrop for Veeva's gains, as the S&P 500 and Nasdaq also climbed to new highs during the same period. Buy, Hold or Sell Veeva Systems? View our complete analysis and fair value estimate and you decide. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. Veeva Systems's recent announcement regarding the adoption of its Clinical Platform applications by over 50 medtech companies signals potential benefits for the company's growth trajectory, aligning well with strategic vendor consolidation trends in the pharmaceutical industry. This development could further bolster revenue as Veeva capitalizes on increased interest in its Data Cloud offerings, promising a more robust market presence. Over the past three years, Veeva Systems achieved a total shareholder return of 58.45%, reflecting solid performance and market confidence. This outpaces the one-year industry return of 32.1%, positioning Veeva favorably in the competitive landscape. As analysts forecast Veeva's revenue to grow by 12% annually over the next three years, the recent news may lend support to these expectations, potentially driving both revenue and earnings higher. Currently, Veeva's share price sits at US$232.81, which is 11.3% below the consensus price target of US$262.35. This gap indicates room for further appreciation should the company's operational efficiencies and AI-driven innovations materialize as anticipated. The combination of favorable industry trends and Veeva's strategic developments could be decisive in meeting or exceeding the market's earnings forecasts and supporting future stock price movements. Gain insights into Veeva Systems' past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:VEEV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
